重型肝炎患者血清sCR1与肝功能损伤程度的相关性研究

研究重型肝炎患者血清sCR1浓度的变化 ,探讨其临床意义。采用酶联免疫吸附法 ,对 3 0例重型肝炎、46例慢性病毒性肝炎及 3 0例正常人群红细胞研究表明 ,重型肝炎及慢性病毒性肝炎患者血清sCR1浓度均高于正常对照人群 (P <0 0 1) ,但重型肝炎患者血清sCR1浓度升高的幅度明显大于慢性病毒性肝炎患者 (P <0 0 1) ,并与CHE、PT及PTA的变化明显相关。重型肝炎患者血清sCR1浓度的变化与肝功能损伤程度密切相关 ,该指标可作为分析重型肝炎患者病情严重程度、判断病情发展及预后的重要参考指标     

慢性病毒性肝炎患者红细胞CR1粘附活性的变化

目的研究慢性病毒性肝炎患者红细胞 CR1粘附活性的变化,探讨其临床意义。方法采用红细胞天然免疫粘附肿瘤细胞功能实验,对80例慢性病毒性肝炎患者及30例正常人的红细胞 CR1分子活性进行测定,同时检测 CHE 等肝功能指标。结果慢性病毒性肝炎患者红细胞 CR1粘附活性显著低于正常人群(P<0.01);慢性肝炎患者红细胞 CR1粘附活性的变化与 CHE、ALT/AST 的变化密切相关,并且随患者病情好转其红细胞 CR1粘附活性相应回升。结论慢性病毒性肝炎患者红细胞 CR1粘附活性可有效地反应肝功能损伤的严重程度,该项可作为判断慢性肝病病情变化的重要指标。     

肝炎肝硬化患者红细胞CR1粘附活性与肝功能损伤程度的相关性研究

目的研究肝炎肝硬化患者红细胞 CR1粘附活性与肝功能损伤严重程度的相关性。方法采用红细胞天然免疫粘附肿瘤细胞的测定方法对88例肝炎肝硬化病人、30例正常人的红细胞 CR1分子粘附活性进行测定,5个或以上红细胞牯附1个肿瘤细胞为一个结合单位,计算粘附率。结果肝炎肝硬化患者红细胞 CR1分子粘附活性显著低于正常人群(P<0.01),失代偿性肝硬化患者的红细胞 CR1分子粘附活性显著低于代偿性肝硬化患者(P<0.01),肝炎肝硬化患者红细胞 CR1分子粘附活性的变化与胆碱酯酶(CHE)密切相关,按 Child Pugh 分级。肝炎肝硬化患者随 Child 积分的升高,其红细胞 CR1分子粘附活性相应下降。结论肝炎肝硬化病人红细胞CR1分子粘附活性的变化与其病情的严重程度密切相关,该项可作为判断肝病患者肝功能损伤程度的重要指标。     

病毒性肝炎患者血清转铁蛋白临床价值再评价

进一步评价血清转铁蛋白变化在病毒性肝炎患者中的临床意义。对 16 1例不同临床类型的病毒性肝炎患者进行血清转铁蛋白检测 ,同时检测凝血酶原时间、血清总胆红素。除急性肝炎患者外 ,各组血清转铁蛋白值与对照组比较有显著性差异 ,慢性重型肝炎患者血清转铁蛋白下降较肝硬化、慢性肝炎 (重度 )均明显 ,比较有显著性差异 (P <0 0 0 1,P <0 0 1) ,血清转铁蛋白与凝血酶原活动度呈正相关 ,而与血清总胆红素无明显相关性。血清转铁蛋白可以作为鉴别急性、慢性肝炎的指标之一 ,血清转铁蛋白随肝实质损害的加重而降低可以作为反映肝细胞坏死程度较敏感可靠的指标 ,对重型肝炎的预后判断有价值。     

病毒性肝炎患者血清胰岛素样生长因子结合蛋白3浓度的测定及对肝功能的评价

探讨各型病毒性肝炎患者血清胰岛素样生长因子结合蛋白-3(Insulin-like growth factor binding protein3,IGFBP-3)浓度的变化及其对肝功能的评价。经ELISA法检测,10例正常对照、10例急性肝炎、10例慢性肝炎中度、11例慢性肝炎重度、12例慢性重型肝炎及11例肝硬化患者血清中IGFBP-3的浓度分别为4891.63±1482.91、4243.88±1086.02、3361.38±584.11、3021.63±946.48、1951.13±791.96及1146.93±443.15ng/ml。除急性肝炎组外,肝炎患者血清IGFBP-3浓度均显著低于正常对照组;血清IGFBP-3浓度与血清白蛋白、前白蛋白呈正相关,而与凝血酶原时间、总胆红素及直接胆红素呈负相关,与AST、ALT无显著相关性。血清IGFBP-3浓度能较好地反映各型病毒性肝炎患者的肝功能损害程度。     

重型肝炎患者凝血与抗凝血系统4项指标检测的临床意义

重型肝炎是病毒性肝炎最严重的一种临床类型,死亡率高,易发展为坏死后肝硬化.重型病毒性肝炎常发生严重的蛋白质合成障碍,维生素K缺乏,导致凝血因子合成减少,出现凝血功能障碍.我们通过对89例重型病毒性肝炎患者血浆凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、纤维蛋白原(FIB)及血小板计数(PLT)的检测,探讨重型病毒性肝炎患者凝血-抗凝血系统的变化.     

胆碱脂酶与血清前白蛋白在各类病毒性肝炎检测中的临床意义

目的 探讨血清胆碱脂酶(Cholinesterase,CHE)与前白蛋白(Prealbumin,PA)在各类病毒性肝炎检测中的临床意义.方法 采用假性CHE速率法与免疫比浊法,对300例各类病毒性肝炎患者及30例健康人员的血清PA与CHE进行测定.结果 各类病毒性肝炎患者血清PA与CHE较对照组比较均有不同程度的下降,降低幅度从高到低依次排序为肝炎后肝硬化、慢性重型肝炎、亚急性重型肝炎、慢性肝炎重度、慢性肝炎中度、急性黄疸型肝炎、慢性肝炎轻度.肝硬化患者从Child-pugh A级到C级,血清PA与CHE呈进行性降低,不同级别测值间差异显著.结论 血清PA与CHE是反映肝脏功能的一项良好指标,可以为临床肝硬化分级提供参考,能对肝硬化患者的预后和是否能耐受手术等作出更加准确、客观的判断.     

重型病毒性肝炎患者生长激素-胰岛素样生长因子轴的临床研究

目的研究重型病毒性肝炎患者GH-IGF轴的变化及其临床意义。方法重型病毒性肝炎患者18例,其中急性重型2例,亚急性重型5例,慢性重型11例;正常对照20例。ELISA法测定血清GH、IGF-1、IGFBP1及IGFBP3,全自动生物化学分析仪常规方法测定肝脏生物化学指标。结果重型肝炎患者血清IGF-1、IGFBP3水平明显降低［(5.5±6.2)μg/ml对(17.6±7.0)μg/ml,(2.4±1.3)μg/ml对(9.4±1.7),P＜0.001］。GH、IGFBP1水平增高［(9.1±12.4)ng/ml对(1.6±2.4)ng/ml,P＜0.05;(67.9±50.2)ng/ml对(45.8±33.1)ng/ml,P＜0.01)］。血清IGF-1与IGFBP3呈正相关(r＝0.91,P＜0.001);IGF-1降低与重型肝炎患者预后密切相关(P＜0.001)。IGF-1＜10μg/ml,预测死亡的符合率为90%;IGF-1＞10μg/ml,预测存活的符合率为89.5%。结论重型病毒性肝炎患者GH-IGF轴发生显著异常变化,GH增高与IGF-1水平降低相矛盾,提示重型病毒性肝炎患者存在生长激素抵抗。血清IGF-1水平可作为预测重型肝炎患者预后的指标。     

重型肝炎患者血清可溶性补体受体Ⅰ型的变化及临床意义

对44例重型肝炎、58例肝硬化及40例正常人群的血清可溶性补体受体Ⅰ型(sCR1)进行研究，现将具体情况报道如下。     

血清总胆固醇水平对重型肝炎诊断及预后判断价值

探讨血清总胆固醇(serum total cholesterol简称sTC)水平对重型病毒性肝炎(重肝)的临床诊断及预后判断价值.方法:对经临床和病理双重确诊的234例慢性乙型病毒性肝炎(慢乙肝)及54例乙型重型肝炎患者sTC进行定量观察,并与肝组织病变程度进行对照分析.结果:sTC水平与慢性乙肝及重型肝炎患者肝组织病变程度Ishak计分呈明显负相关(P＜0.01,r=-0.56).sTC水平均值＜2.07mmol/L者重型肝炎组为77.8%(42/54),重度慢性乙肝组为12.5%(6/48),两组差异有显著性意义(x2=43.46,P＜0.01).重型肝炎组存活率与sTC水平呈明显正相关r=0.65,P＜0.01),经治疗1周,存活组sTC水平稳步回升,死亡组持续下降.结论:sTC水平变化反映了肝脏的合成功能,与肝组织的病理损害程度密切相关.     

慢性肝病患者红细胞免疫功能的研究

目的 探讨慢性肝病患者红细胞免疫粘附功能的变化。方法 检测73例慢性乙型肝炎及肝硬化患者红细胞C_3b受体花环形成率(RBC-C_3bRR)、红细胞免疫复合物花环形成率(RBC-ICRR)及患者的循环免疫复合物(CIC)水平。结果 与正常对照组相比,RBC-C_3bRR在慢性肝炎中、重度及肝硬化患者中明显下降(P<0.01),在慢性肝炎轻度也有显著下降(P<0.05)。而RBC-ICRR在慢性肝炎中重度及肝硬化患者中明显升高(P<0.05)。各型肝病患者CIC均明显升高。结论 慢性肝炎患者的红细胞免疫粘附功能有明显改变,其意义有待进一步研究。     

肝硬化病人血浆胃动素水平的变化及其临床意义

目的 探讨肝硬化病人空腹血浆胃动素水平的变化及其与肝功能损害的关系。方法 应用放免法检测肝炎肝硬化病人、慢性胆炎病人和正常人空腥血浆胃动素,并进行比较。结果 肝硬化病人平均空腥血浆胃动素水平的变化及异常率（〉３１２ｎｇ／ｍｌ为异常）均明显高于慢性肝炎和正常人,且ＣｈｉｌｄＣ级〉Ｂ级〉Ａ级。肝硬化进空腹血浆胃动素水平与血浆白蛋白呈负相关,与血清总胆红素呈正相关。结论 肝硬化病人空腹血浆胃动素水平明显     

Serum matrix metalloproteinase-3 (stromelysin-1) concentration in patients with chronic liver disease.

BACKGROUND/AIMS: Matrix metalloproteinase (MMP)-3 plays an important role in extracellular matrix degradation, because of its broad substrate specificity and its activation of other proMMPs. Our aims in the present study were to determine whether the measurement of serum MMP-3 is clinically useful for assessing ongoing liver fibrolysis in patients with chronic liver disease. METHODS: We measured the serum MMP-3 concentrations with a sandwich enzyme immunoassay in 58 patients with chronic hepatitis, 22 patients with liver cirrhosis, 45 patients with hepatocellular carcinoma and 124 healthy individuals. The liver MMP-3 content was also measured in autopsied livers. RESULTS: Among the healthy controls, the serum levels of MMP-3 were about 2-fold higher in the males than in the females. In this study, the serum MMP-3 results of mainly the male group were analyzed because of the large number of male subjects. Compared to the control level, the mean serum MMP-3 concentration was 55% lower in chronic hepatitis, 53% lower in liver cirrhosis and 46% lower in hepatocellular carcinoma. There was no significant difference in the serum MMP-3 levels among the chronic hepatitis, liver cirrhosis and hepatocellular carcinoma groups. The serum MMP-3 levels were not related to the histological degree of necroinflammation or of liver fibrosis in the patients with chronic hepatitis. No significant difference in serum MMP-3 levels was observed among three Child's subgroups in the group of cirrhotic patients. In the group of patients with hepatocellular carcinoma, the serum MMP-3 levels were not related to the severity of liver function, the HCC tumor size, or the histological differentiation. The serum MMP-3 level was not correlated with serum markers for connective tissue turnover, i.e. procollagen type III peptide, 7S fragment of type IV collagen, hyaluronan and tissue inhibitor of metalloproteinase-1 in the patients with chronic liver disease or hepatocellular carcinoma. CONCLUSIONS: The measurement of serum MMP-3 is of little use for assessing fibrolysis in chronically diseased livers.     

Plasma lecithin: cholesterol acyltransferase activity in liver disease.

The plasma lecithin: cholesterol acyltransferase was determined in patients with various liver diseases and the relationship between this enzyme activity and the other liver function tests were studied including long term observations. Lecithin: cholesterol acyltransferase activity in fulminant hepatitis and liver cirrhosis showed a significant decrease in comparison with normal volunteers. Although the enzyme activity of hepatoma showed significant decrease, they were ascribed to the influence of concomitant liver cirrhosis. The enzyme activity showed insignificant changes in the acute and chronic hepatitis and alcoholic liver disease. Lecithin: cholesterol acyltransferase activity was correlated with the concentration of cholesterolester rather than with the ratio of esters to cholesterol. In addition, it was well correlated with pseudocholine esterase and serum albumin. The lecithin: cholesterol acyltransferase activity in the cases during follow-up period varied in good parallel with cholesterol-esters concentration and pseudocholine esterase in the cases with acute hepatitis; with serum albumin in the cases with liver cirrhosis. Furthermore, it varied inversely with SGPT in the cases with acute hepatitis. In a case with hepatoma, lecithin: cholesterol acyltransferase activity decreased more sharply than the cholesterolesters concentration and serum albumin immediately before death.     

酒精性肝硬化患者血清甲状腺激素水平分析

目的探讨酒精性肝硬化患者血清甲状腺激素水平变化与临床特点。方法 87例肝硬化患者,其中酒精性肝硬化36例（酒精组）、乙肝肝硬化51例（乙肝组）,对照组为健康志愿者11例。根据肝功能对酒精性肝硬化患者进行Child-pugh分级。采用放射免疫法检测患者甲状腺激素血清浓度。结果肝硬化组血清TT3、FT3、TT4和FT4水平均低于对照组（P均〈0.01）,酒精组亦低于乙肝组（P均〈0.05）。酒精组随着肝功能分级升高,FT3和FT4逐渐降低。结论肝硬化患者存在明显的甲状腺激素水平异常,以酒精性肝硬化患者更为突出,甲状腺激素水平随肝功能损伤程度呈动态变化。     

慢性乙型肝炎和肝硬化患者血清可溶性细胞间粘附分子-1的检测

目的 探讨可溶性细胞间粘附分子-1(sICAM-1)在慢性乙型肝炎和肝硬化中的临床意义。方法 应用酶联免疫吸附法检测56例慢性乙型肝炎和18例肝硬化患者血清sICAM-1水平,并同时检测肝功能和T细胞亚群。结果 慢性乙型肝炎和肝硬化患者血清sICAM-1水平明显高于正常人(P<0.01/0.05),且随着肝细胞损伤程度的加重而升高,与T细胞亚群无相关性。结论 血清sICAM-1水平可反映慢性乙型肝炎患者的肝细胞坏死程度。     

Hepatocyte membrane-bound IgG and circulating liver-specific autoantibodies in chronic liver disease: relation to hepatitis B virus serum markers and liver histology

Hepatocytes isolated from 101 biopsies were examined for membrane-bound IgG. The sera of the patients were tested for anti-liver-specific lipoprotein by radioimmunoassay and for liver membrane autoantibody (by indirect immunofluorescence on isolated rabbit hepatocytes. The seven patients with normal liver or minor nonspecific alterations were negative for membrane IgG and serum antibodies. Membrane IgG with granular distribution was found in 41 patients [21 hepatitis B virus-related chronic active hepatitis (CAH), 3 cryptogenic CAH, 3 chronic persistent hepatitis, 6 prolonged viral hepatitis, 1 alcoholic cirrhosis, and 6 primary biliary cirrhosis]. Membrane IgG with linear fluorescence pattern was detected in 12 cases (4 autoimmune CAH, 3 HBsAg-positive CAH, 2 alcoholic cirrhosis, 1 anti-HBc positive CAH, 1 cryptogenic CAH, and 1 prolonged viral hepatitis). A strong association between granular IgG and serum HBsAg was found. Nuclear localization of IgG was found in 34 patients and correlated with the positivity of granular membrane IgG. The highest prevalence of anti-liver-specific lipoprotein was found in primary biliary cirrhosis and autoimmune CAH cases which were also positive for liver membrane autoantibody. No relationship was found between the presence of membrane IgG and circulating liver-specific autoantibodies. Membrane IgG and anti-liver-specific lipoprotein correlated with the presence of moderate and severe portal inflammatory infiltration but not with piecemeal necrosis or transaminase levels. Eleven of the twelve patients with linear membrane IgG presented chronic active liver disease with moderate to severe signs of liver damage. Therefore, it is suggested that, while granular membrane IgGs are related to hepatitis B virus, antigenic expression on the hepatocyte surface and/or the presence of immune complexes, linear membrane IgG could play a role in the immunopathogenesis of liver cell damage particularly in "autoimmune" cases which present high percentages of positive cells liver-specific autoantibodies.